Treatment with anticoagulants in cerebral events (TRACE).
90 patients with acute stroke and a concomitant cardiac embolism source or a symptomatic high-grade stenosis of an extra-or intracranial vessel received in a mulitcenter, randomized, controlled study either Enoxaparin 1 mg/kg BW s.c. b.i.d. or i.v. heparin aPTT-adjusted daily for 8 +/- 2 days as secondary prophylaxis. There were no significant differences between the two groups regarding cerebral and systemic embolic events, bleeding complications, length of hospital stay, number of diagnostic and therapeutic measures and outcome after three months. This suggests that Enoxaparin, which is easier to administer and monitor, is a safe drug in patients with acute cerebral events.
Woessner
Ralph
R
Department of Neurology and Intensive Stroke Unit, Westpfalz-Klinikum GmbH, 67655 Kaiserslautern, Germany.
Grauer
Markus
M
Bianchi
Oliver
O
Mueller
Martin
M
Moersdorf
Stefan
S
Berlit
Peter
P
Goertler
Michael
M
Grotemeyer
Karl-Heinz
KH
Sliwka
Ulrich
U
Stoll
Martin
M
Treib
Johannes
J
D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage / Q000009:adverse effects; D003251:Constriction, Pathologic; D016903:Drug Monitoring; D004617:Embolism; D017984:Enoxaparin / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006470:Hemorrhage; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000150:complications / Q000188:drug therapy*; D016896:Treatment Outcome
D000925:Anticoagulants; D017984:Enoxaparin; D006493:Heparin